Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20152016Delta
CHF (in Million)%CHF (in Million)%
Drugs2,045100%2,418100% +18.23%
Sales per Regions
20152016Delta
CHF (in Million)%CHF (in Million)%
United States1,02650.1%1,30654% +27.35%
Europe633.2031%620.3225.7% -2.03%
Japan190.069.3%258.2610.7% +35.88%
Other167.868.2%201.648.3% +20.12%
Switzerland28.391.4%31.691.3% +11.64%
Managers
NameAgeSinceTitle
Jean-Paul Clozel621997Chief Executive Officer & Executive Director
Jean-Pierre Garnier692011Chairman
Otto Schwarz622008Chief Operating Officer & Executive Vice President
André C. Muller, MBA542013Chief Financial Officer & Executive Vice President
Martine Clozel, MD621997Chief Scientific Officer & Senior Vice President
Michael Jacobi, PhD642009Independent Non-Executive Director
Jean Pierre Malo CFA, MBA632004Independent Non-Executive Director
Juhani Anttila63-Independent Non-Executive Director
Robert J. Bertolini, CPA54-Independent Non-Executive Director
Peter Gruss, PhD682012Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 107,761,427 93,832,489 87.1% 4,654,225 4.3% 87.1%
Shareholders
NameEquities%
Rudolf Maag, MBA 5,467,305 5.07%
Jean-Paul Clozel 5,418,507 5.03%
Norges Bank Investment Management 3,333,050 3.09%
Actelion Ltd. 3,257,940 3.02%
The Vanguard Group, Inc. 2,057,855 1.91%
UBS AG (Investment Management) 1,983,833 1.84%
Bellevue Asset Management AG 1,716,948 1.59%
Credit Suisse AG 1,303,814 1.21%
Wellington Management Co. LLP 716,233 0.66%
Artisan Partners LP 644,843 0.60%
Holdings
NameEquities%Valuation
Actelion Ltd (ATLN) 3,257,9403.02%920,145,533 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ACTELION LTD26.44%30 320
AMGEN, INC.12.58%121 201
CELGENE CORPORATION8.16%97 650
GILEAD SCIENCES, INC.-4.73%87 742
REGENERON PHARMACEUTIC..1.42%39 496
VERTEX PHARMACEUTICALS..57.92%29 134
GENMAB A/S16.54%11 806
TESARO INC2.94%7 448
EXELIXIS, INC.47.55%6 454
BIOVERATIV INC0.00%6 239
HUALAN BIOLOGICAL ENGI..--.--%4 860
NEUROCRINE BIOSCIENCES..38.55%4 693
TONGHUA DONGBAO PHARMA..-3.42%4 432
KITE PHARMA INC79.68%4 418
BIOCON LTD19.02%3 643
BLUEBIRD BIO INC42.22%3 592
PEPTIDREAM INC10.69%3 426
CHINA BIOLOGIC PRODUCT..10.82%3 227
INTERCEPT PHARMACEUTIC..5.63%2 850
ULTRAGENYX PHARMACEUTI..-7.52%2 713
JUNO THERAPEUTICS INC33.16%2 647
Sector Bio Therapeutic Drugs
Actelion Ltd : Connections
Alzheon, Inc.
Actelion Pharmaceuticals Italia SRL
Actelion Pharmaceuticals Hellas SA
Avalon Advisors LLC
Actelion Pharmaceuticals Japan Ltd.
Actelion Pharmaceuticals Korea Ltd.
The Francis Crick Institute Ltd.
Actelion Pharmaceuticals Sverige AB
Society of Financial Analysts of Houston
ArgYou AG
ValCrea AG
Max Planck Institute For Biophysical Chemistry
Newman's Own Foundation
Anttila & Co. Advisors
Hilti Martin Family Trust
Hilti AG
Actelion Pharmaceuticals Ltd.
Deutsche Akademie der Technikwissenschaften eV
Actelion Pharmaceuticals UK Ltd.
Deutsche Forschungsgemeinschaft
CFA Institute
Deutsche Akademie der Naturforscher Leopoldina eV
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  
- Reuters Code :  ATLN.S
- Datastream Code :  S:ATLN
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem